Bard Financial Services Inc. Has $3.09 Million Stake in Gilead Sciences, Inc. $GILD

Bard Financial Services Inc. cut its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 3.5% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 27,825 shares of the biopharmaceutical company’s stock after selling 1,020 shares during the quarter. Bard Financial Services Inc.’s holdings in Gilead Sciences were worth $3,085,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Smallwood Wealth Investment Management LLC bought a new position in shares of Gilead Sciences during the first quarter worth about $25,000. Activest Wealth Management increased its position in Gilead Sciences by 2,837.5% during the 1st quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 227 shares during the period. Goodman Advisory Group LLC acquired a new stake in Gilead Sciences during the 1st quarter valued at approximately $29,000. Colonial Trust Advisors raised its holdings in Gilead Sciences by 304.3% during the 1st quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 213 shares during the last quarter. Finally, Core Alternative Capital lifted its position in shares of Gilead Sciences by 370.8% in the 1st quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company’s stock worth $34,000 after purchasing an additional 241 shares during the period. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Trading Down 2.8%

NASDAQ GILD opened at $114.55 on Monday. The company has a market cap of $142.13 billion, a price-to-earnings ratio of 22.82, a P/E/G ratio of 0.78 and a beta of 0.36. Gilead Sciences, Inc. has a 52 week low of $81.57 and a 52 week high of $121.83. The business has a 50 day moving average price of $114.04 and a 200-day moving average price of $110.08. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The company had revenue of $7.08 billion for the quarter, compared to analysts’ expectations of $6.95 billion. During the same period last year, the business earned $2.01 EPS. Gilead Sciences’s quarterly revenue was up 1.4% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, equities analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, September 29th. Stockholders of record on Monday, September 15th will be paid a $0.79 dividend. The ex-dividend date of this dividend is Monday, September 15th. This represents a $3.16 annualized dividend and a dividend yield of 2.8%. Gilead Sciences’s dividend payout ratio is 62.95%.

Analysts Set New Price Targets

GILD has been the subject of a number of analyst reports. Truist Financial raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and lifted their target price for the stock from $108.00 to $127.00 in a research note on Friday, August 8th. Needham & Company LLC upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $133.00 target price on the stock in a research report on Friday, July 25th. Daiwa Capital Markets raised Gilead Sciences from a “neutral” rating to an “outperform” rating and set a $128.00 target price for the company in a research note on Tuesday, August 19th. Dbs Bank raised Gilead Sciences to a “moderate buy” rating in a research note on Friday, September 5th. Finally, Daiwa America upgraded Gilead Sciences from a “hold” rating to a “strong-buy” rating in a report on Tuesday, August 19th. Three investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $115.39.

Insider Buying and Selling

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock in a transaction on Thursday, August 28th. The shares were sold at an average price of $113.63, for a total transaction of $1,136,300.00. Following the transaction, the chief executive officer directly owned 595,725 shares of the company’s stock, valued at $67,692,231.75. The trade was a 1.65% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction on Friday, August 15th. The stock was sold at an average price of $118.53, for a total transaction of $296,325.00. Following the completion of the sale, the chief financial officer owned 160,110 shares of the company’s stock, valued at approximately $18,977,838.30. The trade was a 1.54% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 76,500 shares of company stock valued at $8,765,395 in the last 90 days. Insiders own 0.27% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.